Galimedix Therapeutics, a clinical-stage biotechnology company, has announced the initiation of a phase 2 trial to assess the efficacy and safety of its GAL-101 eye drops for patients with geographic atrophy (GA). GAL-101 is a small molecule targeting misfolded amyloid-beta (Aβ) monomers, which form toxic aggregates implicated in neurodegenerative diseases of the retina and brain. Preclinical studies have shown that GAL-101 protects neuronal retinal cells from damage, and phase 1 testing demonstrated an excellent safety profile, the company said in a press release.

The eDREAM study (NCT06659549) will enroll up to 110 patients in a randomized, double-blind, placebo-controlled design. The trial’s primary endpoint is the reduction in the rate of geographic atrophy lesion growth, a key indicator of disease progression. Secondary outcomes include photoreceptor degeneration rates and functional measures such as retinal sensitivity using microperimetry. The study will begin enrolling soon, with an estimated completion date of March 2027.